| Year | Firm | Client | Amount | Doc |
|---|---|---|---|---|
| 2026 3rd Quarter - Report |
NOVEL STRATEGIES (FKA) PRISM GROUP | MASSACHUSETTS BIOTECHNOLOGY COUNCIL | $10,000 | |
| 2026 Registration |
NOVEL STRATEGIES (FKA) PRISM GROUP | MASSACHUSETTS BIOTECHNOLOGY COUNCIL | — | |
| 2026 3rd Quarter - Report |
NOVEL STRATEGIES (FKA) PRISM GROUP | GENEVANT SCIENCES, INC. | $30,000 | |
| 2026 3rd Quarter - Report |
NOVEL STRATEGIES (FKA) PRISM GROUP | THE ALLIANCE FOR LONGEVITY INITIATIVES | $20,000 | |
| 2026 3rd Quarter - Report |
NOVEL STRATEGIES (FKA) PRISM GROUP | INCUBATE | $30,000 | |
| 2026 2nd Quarter - Report |
NOVEL STRATEGIES (FKA) PRISM GROUP | GENEVANT SCIENCES, INC. | $30,000 | |
| 2026 AMENDED |
NOVEL STRATEGIES (FKA) PRISM GROUP | GENEVANT SCIENCES, INC. | — | |
| 2026 AMENDED |
NOVEL STRATEGIES (FKA) PRISM GROUP | GENEVANT SCIENCES, INC. | — | |
| 2026 2nd Quarter - Report |
NOVEL STRATEGIES (FKA) PRISM GROUP | THE ALLIANCE FOR LONGEVITY INITIATIVES | $20,000 | |
| 2026 2nd Quarter - Report |
NOVEL STRATEGIES (FKA) PRISM GROUP | INCUBATE | $30,000 |